An engineered S1P chaperone attenuates hypertension and ischemic injury
We report the development of a soluble carrier for S1P, ApoM-Fc, which activated S1P receptors in a sustained manner and promoted endothelial function. In contrast, ApoM-Fc did not modulate circulating lymphocyte numbers, suggesting that it specifically activated endothelial S1P receptors. ApoM-Fc administration reduced blood pressure in hypertensive mice, attenuated myocardial damage after ischemia/reperfusion injury, and reduced brain infarct volume in the middle cerebral artery occlusion model of stroke. Our proof-of-concept study suggests that selective and sustained targeting of endothelial S1P receptors by ApoM-Fc could be a viable therapeutic strategy in vascular diseases.
Source: Signal Transduction Knowledge Environment - Category: Science Authors: Swendeman, S. L., Xiong, Y., Cantalupo, A., Yuan, H., Burg, N., Hisano, Y., Cartier, A., Liu, C. H., Engelbrecht, E., Blaho, V., Zhang, Y., Yanagida, K., Galvani, S., Obinata, H., Salmon, J. E., Sanchez, T., Di Lorenzo, A., Hla, T. Tags: STKE Research Articles Source Type: news
More News: Brain | Environmental Health | Hypertension | Ischemic Stroke | Neurology | Stroke | Study